Keylika (YC S22) — Redefining the standard of care for iron deficiency anemia
Keylika is an early stage biopharma startup developing metal-based drugs using a platform synthesis technology to treat unmet medical needs. We then administer these drugs using proven delivery technologies to effect the best clinical outcomes.
Keylika is a Y Combinator company in the Summer 2022 batch. Its directory entry describes it as: Redefining the Standard of Care for Iron Deficiency Anemia. The founders listed are Buddha Chaudhuri (Founder), Frederik Ceyssens (Founder) (Y Combinator directory entry, July 22, 2022).
Get an email when Keylika changes status, grows its team or files a funding notice. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
Keylika is an early stage biopharma startup developing metal-based drugs using a platform synthesis technology to treat unmet medical needs. We then administer these drugs using proven delivery technologies to effect the best clinical outcomes.
Our first product is a small molecule iron drug (new molecular entity) delivered by a wearable skin patch to treat Iron Deficiency Anemia (IDA), with significantly higher safety, efficacy and tolerability over existing treatments. This is poised to be a best-in-class, potentially breakthrough therapy for treating iron deficiency without any GI side-effects (eg. nausea, constipation, diarrhea, etc.) typically associated with oral iron supplements, and without the risks, costs and side-effects associated with IV iron infusions. When approved, Keylika’s proprietary transdermal iron will be the world's first prescription iron patch. Iron deficiency is a hugely understated problem affecting about 1.6 billion people worldwide and more than 30 million in the US alone, translating to a $17B US market.
Buddha Chaudhuri
Founder
Frederik Ceyssens
Founder
Founders, titles and bios as the company published them. Photographs are our own copies of the ones on that record, so they do not break when the original link expires.
One of 65 companies held here in Healthcare › Therapeutics.
No investor is drawn from a Form D — the form states how many invested and never who. The one investor on this graph is named because a batch has exactly one.
Want the whole picture on Keylika?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Keylika: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Keylika covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
1 cited source found
Plus the sections for what you are deciding, which you pick after ordering.
You get an alert in MentionFox the next time this company shows up.
Is this you?
If you're behind Keylika: acceptance into a YC batch is one of the few weeks a young company gets looked up by people who matter — investors, other founders, press. FoxPlug turns the commits, deploys, and releases you're already making into that story automatically, so anyone who looks finds something current. GetFoxChat puts a guide on your own site so the people YC's own page just sent you don't read one line and leave.
